MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
$70.827M
Unit: Million (M) dollars
Positive Cash Flow Breakdown
Proceeds from 2025 credit facili...
Sales of marketable securities
Amortization expense
Others
Negative Cash Flow Breakdown
Acquisition of azstarys (net of ...
Intangible asset amortization
Commercial expenses
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Product revenues, net
199.878
193.52
205.449
209.361
Cost of product revenues (excluding intangible asset amortization)
26.633
20.801
21.598
24.717
Intangible asset amortization and impairment
-
-
-
55.473
Intangible asset amortization
62.953
55.473
221.892
-
Commercial expenses
46.403
47.357
39.656
36.931
Corporate expenses
12.163
14.54
11.555
10.905
Medical expenses
7.899
7.148
6.114
7.775
Technical operations expenses
0.165
0.25
0.163
0.129
Stock-based compensation expense
14.484
10.88
9.753
9.811
Other segment items
25.48
6.175
0.38
1.533
Interest expense
19.519
15.862
19.292
21.767
Interest income
2.289
3.706
11.289
-
Loss on extinguishment of debt
-
-
-15.994
-
Interest income
-
-
-
12.332
Provision for income taxes
1.519
4.244
12.073
11.929
Net (loss) income
-15.051
14.496
16.963
31.507
Amortization expense
62.953
55.473
55.473
166.419
Depreciation expense
1.812
0.463
0.923
1.033
Deferred income taxes
-7.155
-0.968
-10.072
-12.132
Stock-based compensation expense
14.484
10.88
9.753
9.811
Non-cash lease benefit
-0.084
-0.091
-0.104
0.503
Loss on extinguishment of debt
-
-
-15.994
-
Non-cash interest expense for amortization of debt discount and issuance costs
1.082
0.819
1.276
1.343
Non-cash interest expense for deferred royalty obligation
-
-
0.95
-
Net accretion for deferred royalty obligation
-
-1.595
-
-0.348
Net (amortization) accretion for deferred royalty obligation
-0.206
-
-
-
Net amortization of premiums and discounts on investments
0.045
0.178
0.254
0.23
Change in fair value of contingent consideration
0
0
-0.019
-0.019
Accounts receivable
-2.129
17.434
-22.621
20.926
Inventory
0.597
1.829
2.861
-0.096
Prepaid expenses and other assets
8.232
-4.132
8.185
-21.337
Accounts payable
0.317
-3.827
3.045
-3.283
Accrued liabilities
12.275
-4.152
10.705
-8.114
Accrued rebates, returns and discounts
7.878
-0.575
8.658
2.432
Operating lease assets and liabilities
-
-
0.015
0.01
Deferred revenue
-0.166
-0.167
-0.167
-0.055
Net cash provided by operating activities
71.323
57.113
123.048
78.438
Acquisition of azstarys (net of cash acquired)
655.403
-
0
-
Purchases of property and equipment
0.496
0.27
0.689
0.188
Purchases of marketable securities
1.991
18.109
39.222
45.245
Sales of marketable securities
151.805
-
-
-
Maturities of marketable securities
3.494
20.006
19.842
45.334
Net cash used in investing activities
-502.591
1.627
-20.069
-30.868
Proceeds from issuances of common stock from employee stock purchase plan
0
0.947
0
0.857
Proceeds from the exercise of stock options
0.481
0.394
0.985
1.435
Payments made for employee stock tax withholdings
0.646
15.433
0.861
0.964
Repurchases of common stock
-
-
0
0
Proceeds from 2025 credit facility
299.504
-
-
-
Repayment of term notes
7.25
7.25
587.12
16.146
Proceeds from issuance of 2025 credit facility, net of debt discount and issuance costs
-
-
565.175
-
Payments made for deferred purchase price for acquisition
0
0
0
0
Proceeds from term note modification, net of fees paid to lender
-
-
0
-
Proceeds from issuances of 2029 convertible notes, net of issuance costs
-
-
0
-
Repurchase of 2026 convertible notes, including premium
-
-
0
-
Redemption of 2026 convertible notes, including premium and redemption costs
-
-
0
-
Repayment of assumed debt from ironshore acquisition
-
-
0
-
Net cash provided by (used in) financing activities
292.089
-21.342
-21.821
-14.818
Net (decrease) increase in cash, cash equivalents and restricted cash
-139.179
37.398
81.158
32.752
Cash, cash equivalents and restricted cash at beginning of period
289.556
252.158
171
96.612
Cash, cash equivalents and restricted cash at end of period
150.377
-
-
-
Cash and cash equivalents
129.467
-
-
-
Restricted cash
20.91
-
-
-
Total cash, cash equivalents and restricted cash
150.377
289.556
252.158
171
Page 1
Unit: Million (M) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from 2025 credit
facility
$299.504M
Amortization expense
$62.953M
(-43.26%↓ Y/Y)
Stock-based compensation
expense
$14.484M
(-35.17%↓ Y/Y)
Proceeds from the
exercise of stock options
$0.481M
(-74.14%↓ Y/Y)
Accrued liabilities
$12.275M
(201.56%↑ Y/Y)
Accrued rebates,
returns and discounts
$7.878M
(195.62%↑ Y/Y)
Accounts receivable
-$2.129M
(86.27%↑ Y/Y)
Depreciation expense
$1.812M
(-18.60%↓ Y/Y)
Non-cash interest
expense for...
$1.082M
(-60.25%↓ Y/Y)
Accounts payable
$0.317M
(-95.44%↓ Y/Y)
Net cash provided by
(used in) financing...
$292.089M
(496.83%↑ Y/Y)
Net cash provided by
operating activities
$71.323M
(-44.21%↓ Y/Y)
Canceled cashflow
$7.896M
Canceled cashflow
$31.536M
Product revenues, net
$199.878M
(-45.35%↓ Y/Y)
Interest income
$2.289M
Net (decrease)
increase in cash, cash...
-$139.179M
(-434.28%↓ Y/Y)
Canceled cashflow
$363.412M
Sales of marketable
securities
$151.805M
Maturities of marketable
securities
$3.494M
(-88.64%↓ Y/Y)
Repayment of term notes
$7.25M
(-77.55%↓ Y/Y)
Payments made for
employee stock tax...
$0.646M
(-94.14%↓ Y/Y)
Net (loss) income
-$15.051M
(-204.52%↓ Y/Y)
Prepaid expenses and
other assets
$8.232M
(-61.02%↓ Y/Y)
Deferred income taxes
-$7.155M
(-107.21%↓ Y/Y)
Inventory
$0.597M
(-76.93%↓ Y/Y)
Net (amortization)
accretion for deferred...
-$0.206M
Deferred revenue
-$0.166M
Non-cash lease benefit
-$0.084M
(-40.00%↓ Y/Y)
Net amortization of
premiums and discounts on...
$0.045M
(-92.35%↓ Y/Y)
Canceled cashflow
$202.167M
Net cash used in
investing activities
-$502.591M
(-3890.40%↓ Y/Y)
Canceled cashflow
$155.299M
Intangible asset
amortization
$62.953M
Commercial expenses
$46.403M
(-45.35%↓ Y/Y)
Cost of product
revenues (excluding...
$26.633M
(-45.76%↓ Y/Y)
Other segment items
$25.48M
(928.66%↑ Y/Y)
Interest expense
$19.519M
(-52.68%↓ Y/Y)
Stock-based compensation
expense
$14.484M
(-35.17%↓ Y/Y)
Corporate expenses
$12.163M
(-47.32%↓ Y/Y)
Medical expenses
$7.899M
(-50.21%↓ Y/Y)
Provision for income taxes
$1.519M
(-73.57%↓ Y/Y)
Technical operations
expenses
$0.165M
(-29.49%↓ Y/Y)
Acquisition of azstarys (net
of cash acquired)
$655.403M
Purchases of marketable
securities
$1.991M
(-95.32%↓ Y/Y)
Purchases of property and
equipment
$0.496M
(-42.53%↓ Y/Y)
Buy us a coffee
COLLEGIUM PHARMACEUTICAL, INC (COLL)
COLLEGIUM PHARMACEUTICAL, INC (COLL)